GSK plc
HS235
pulmonary hypertension
Resolved
69days ago
Catalyst readout · Apr 29, 2026
What's at stake
A key catalyst for HS235 (pulmonary hypertension) is expected Apr 29, 2026.
Primary source
· SEC 6-K
verified 12h ago
“Pipeline acquisitions completed for new high-potential best-in-class assets: ozureprubart for food allergies; and HS235, pulmonary hypertension”